Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to a placebo.
According to the announcement, partial results were released on Tuesday with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete.
Partial results indicate that at selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg (i.e., 23%) decrease in BP relative to placebo, with volunteers averaging a notable reduction of 7.0% (p<0.001) in systolic pressure.
In addition, over the same period, volunteers averaged a significant reduction of 5.3% (p<0.001) in MAP and a significant reduction of 3.5% in diastolic pressure relative to an increase in diastolic pressure (-0.8 vs. +2.7; p<0.001) from baseline with DehydraTECH-CBD relative to placebo treatment.
The company noted that these numbers are particularly remarkable because many drugs currently used to treat hypertension require several weeks of treatment and/or combination dosing before they produce comparable results.
Lexaria will continue to evaluate the results of its first two human clinical hypertension studies before its upcoming pulmonary human clinical hypertension study of 2021 begins.
“Over the initial 24 hours, Lexaria’s 2021 hypertension program is now delivering blood pressure reduction results competitive with — and in some cases, even superior to — established oral pharmaceutical hypertension drugs,” said Lexaria CEO Chris Bunka in the press release.
“DehydraTECH-CBD demonstrated a sustained and augmented effect upon blood pressure attenuation throughout the day, indicating the effectiveness of the repeat dosing treatment schedule used in this study,” Bunka added.
To view the full press release, visit https://cnw.fm/OGIp9
Photo by Julia Teichmann from Pixabay
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.